MedTrace Logo

DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)

NCT01752894 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 776

Last updated 2019-03-21

No results posted yet for this study

Summary

The purpose of the study is 1\> to compare neointimal stent coverage after OCT-guided vs. Angio-guided PCI, 2\> to compare neointimal stent coverage at 3 months after EES vs BES implantation, 3\> to determine the duration of dual antiplatelet therapy by OCT measurement at 3 months

Conditions

  • Ischemic Heart Disease

Interventions

DEVICE

Angio-guided PCI with EES or BES

Angio-guided intervention

DEVICE

OCT-guided PCI with EES or BES

OCT-guided intervention

DEVICE

PCI with BES under angio-guide or OCT guide

biolimus A9-eluting stent.

DEVICE

PCI with EES under angio-guide or OCT guide

everolimus eluting stent.

DRUG

Keep DAPT

maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.

DRUG

Discontinue DAPT

discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-02
Primary Completion
2017-04-11
Completion
2017-04-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01752894 on ClinicalTrials.gov